Immunocytochemical demonstration and significance of p21 ras family oncogene product in benign and malignant breast disease.
It has been suggested that the immunocytochemical demonstration of the p21 ras oncogene product is a useful marker of malignancy in breast disease. We have studied the reactivity of a series of specimens of benign and malignant breast disease with the anti ras p21 monoclonal antibody Y13-259, and shown widespread positive staining in both benign and malignant (including metastatic) disease as well as in adjacent 'normal' epithelium. In addition some staining of stromal cells as well as nerve fibres was observed. Our results suggest that the presence of ras p21 protein as demonstrated by this antibody is not a useful marker of malignancy or of proliferating epithelium but is rather a normal feature of certain cell types.
D000232:Adenofibroma / Q000032:analysis; D001940:Breast / Q000378:metabolism / Q000473:pathology; D001941:Breast Diseases / Q000378:metabolism* / Q000473:pathology; D001943:Breast Neoplasms / Q000032:analysis* / Q000473:pathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000032:analysis; D002471:Cell Transformation, Neoplastic / Q000032:analysis; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D015689:Oncogene Protein p21(ras); D009856:Oncogene Proteins, Viral / Q000032:analysis*; D009857:Oncogenes; D014176:Protein Biosynthesis
D009856:Oncogene Proteins, Viral; D015689:Oncogene Protein p21(ras)